Core Insights - Bioventus reported a solid Q4 performance with revenue of $158 million, reflecting a 3% increase year-over-year and a 10% organic growth after adjusting for the Advanced Rehabilitation divestiture [7][11]. - The company highlighted strong performance in Pain Treatments, which grew 15% in Q4, driven by the DUROLANE product and a shift towards single-injection therapies [4][9]. - Management provided guidance for 2026, projecting net sales of $600–610 million and adjusted EPS of $0.73–0.77, indicating expected growth in both revenue and profitability [10][21]. International Performance - International revenue remained unchanged year-over-year in Q4, but organic growth was reported at 11% for the full year, attributed to improved commercial execution and talent additions [1]. - The timing of distributor orders impacted Q4 growth, which was noted by management [1]. Restorative Therapies - Revenue in Restorative Therapies declined by 26% due to the divestiture of Advanced Rehabilitation, but organic growth was still 10%, largely driven by strong performance from the EXOGEN product [2][9]. Surgical Solutions - Surgical Solutions saw a revenue growth of 3%, with Ultrasonics facing tough comparisons against a record high from the previous year [3]. - Generator revenue in Q4 was noted as the third-highest total ever for the company, indicating a solid foundation for future growth [3]. Pain Treatments - Pain Treatments revenue advanced by 15% in Q4, with a strong emphasis on the hyaluronic acid franchise and favorable demographics for knee osteoarthritis [4]. - The performance was significantly driven by volume, with DUROLANE leading the results [4]. Financial Performance - Adjusted EBITDA for the quarter was $37 million, a 30% increase year-over-year, with an adjusted EBITDA margin of 23%, up 490 basis points from the previous year [6][11]. - The company reported a quarterly record for cash from operations at $38 million, nearly double the prior-year quarter, contributing to a full-year cash flow of nearly $75 million, a 92% increase [13][14]. Balance Sheet and Leverage - Bioventus ended the quarter with $51 million in cash and $294 million in outstanding debt, with a reduction of $29 million in debt during the quarter [15]. - The net leverage ratio declined to below 2.5x, with expectations to be well below 2x by the end of 2026 [15]. 2026 Strategy and Investments - The company plans to allocate approximately $13 million in incremental investments across growth drivers such as PNS, PRP, Ultrasonics, and international expansion [17][18]. - Management expects the combination of PNS and PRP to contribute at least 200 basis points of growth in 2026, with further acceleration anticipated in 2027 [19]. Guidance and Expectations - For 2026, management expects Q1 to be below the implied guidance range, with growth anticipated to accelerate in Q2 and the second half of the year [22]. - The company does not anticipate any additional impact from U.S. dollar fluctuations for the year [25].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the Advanced Rehabilitation divestiture [23][24] - Adjusted EBITDA increased by $8 million to $37 million, representing a 30% increase year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points [24][27] - Cash flow from operations totaled $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full-year cash flow increase of 92% [28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [25] - Surgical solutions revenue grew by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [25] - Restorative therapies revenue declined by 26% due to the divestiture, but organic growth was 10% excluding this impact, driven by strong performance from EXOGEN [26] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged year-over-year, but organic growth was 10%, with an overall growth of 11% for the year [26] - The company expects to continue its positive momentum in international markets due to talent additions and improved commercial execution [26] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [6][7] - In 2026, the company plans to invest approximately $13 million in growth drivers, including PNS, PRP, Ultrasonics, and international business [13][16] - The focus will be on driving above-market growth, expanding profitability, and strengthening cash flow, with an expected EBITDA margin of approximately 20% for 2026 [19][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and its ability to deliver above-market revenue growth while increasing investments in growth drivers [20][66] - The company anticipates earnings growth to outpace revenue growth, driven by strong gross margins and disciplined resource allocation [19][30] Other Important Information - The company has refinanced its term loan, enhancing liquidity and driving interest expense savings [12] - The company expects cash from operations to range between $82 million and $87 million in 2026, an increase of approximately 10%-17% [30] Q&A Session Summary Question: Growth contribution year-over-year from price and thoughts on GELSYN-3 and SUPARTZ FX - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][36] Question: Assumptions by segment for 2026 growth - Pain treatments are expected to see mid to high single-digit growth, while restorative therapies are projected to grow low to mid-single digits [38][39] Question: Tailwind from favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [46] Question: Learnings from the PNS pilot phase and confirmation of 200 basis point growth - Positive feedback was received on the technology's power and ease of use, and management reaffirmed the expectation of a minimum of 200 basis points growth from PNS and PRP [48][50]

Financial Data and Key Metrics Changes - The company reported Q4 revenue of $158 million, a 3% increase year-over-year, with organic growth at 10% after adjusting for the Advanced Rehabilitation divestiture [24][30] - Adjusted EBITDA increased by $8 million to $37 million, representing a 30% increase, with an adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the prior year [25][28] - Cash flow from operations reached approximately $38 million, nearly doubling compared to Q4 last year, contributing to a full-year cash flow increase of 92% [29] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [26] - Surgical solutions revenue increased by 3%, although Ultrasonics faced tough comparisons to prior year capital sales [26] - Restorative therapies revenue declined by 26% due to the divestiture, but organic growth was 10% when excluding this impact [27] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged year-over-year, but organic growth climbed 10%, with a full-year growth of 11% [27] - The company noted that the pain treatments business is expected to continue growing above market rates, with a focus on volume-driven growth [36][42] Company Strategy and Development Direction - The company aims to build a $1 billion leading med tech company by focusing on accelerating revenue growth and expanding capital allocation options through strong free cash flow [6][20] - Key objectives for 2026 include targeted investments in growth drivers, driving profitability that exceeds revenue growth, and strengthening cash flow [13][19] - The company plans to allocate approximately $13 million towards growth drivers such as PNS, PRP, Ultrasonics, and international business expansion [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver above-market revenue growth while improving earnings and cash flow [67] - The company anticipates that earnings growth will outpace revenue growth, supported by a leading gross margin and disciplined resource allocation [20][31] - Management highlighted the importance of a long-term approach to profitable growth, particularly in the HA business [42] Other Important Information - The company refinanced its term loan, enhancing liquidity and reducing interest expenses, which is expected to continue benefiting the company in 2026 [13] - The company is focused on maintaining an EBITDA margin of approximately 20% for 2026 while investing in future growth [20] Q&A Session Summary Question: Growth contribution year-over-year from price and thoughts on GELSYN-3 and SUPARTZ FX - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [36] Question: Assumptions by segment for 2026 guidance - Management expects low to mid-single digit growth for restorative therapies, mid to high single digit growth for pain treatments, and double-digit growth for surgical solutions [39][40] Question: Tailwind from favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [48] Question: Learnings from PNS pilot phase and confirmation of 200 basis point growth - Management confirmed positive feedback from the PNS pilot and reaffirmed the expectation of a minimum of 200 basis points growth from PNS and PRP combined [52] Question: Near-term expectations for Ultrasonics and team building for PNS - Management emphasized a focus on the spine space for Ultrasonics and noted the hiring of a dedicated general manager for PNS to drive growth [61]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $158 million, a 3% increase compared to the prior year, with organic growth at 10% after adjusting for the impact of the Advanced Rehabilitation divestiture [20][21] - Adjusted EBITDA for the quarter was $37 million, an increase of $8 million or 30% year-over-year, with an Adjusted EBITDA margin of 23%, expanding by 490 basis points compared to the previous year [21][22] - Cash flow from operations totaled approximately $38 million, nearly doubling compared to the fourth quarter last year, contributing to a full year objective of nearly doubling cash flow from operations, achieving a 92% increase for the year [26][28] Business Line Data and Key Metrics Changes - In the pain treatments segment, revenue grew by 15% in Q4, driven by strong volume growth of DUROLANE and account wins [23] - Surgical solutions revenue increased by 3%, with Ultrasonics facing tough comparisons to prior year capital sales [23] - Restorative therapies revenue declined by 26% due to the divestiture of the Advanced Rehabilitation business, but organic growth was 10% excluding this impact [24] Market Data and Key Metrics Changes - The international segment's revenue remained unchanged compared to the prior year, with organic growth climbing 10% [24] - The international segment achieved 11% organic growth for the year, supported by a new team and improved commercial execution [24] Company Strategy and Development Direction - The company aims to accelerate revenue growth while strengthening earnings power and expanding capital allocation options through consistent growth in free cash flow [5][10] - In 2026, the company plans to invest approximately $13 million in growth drivers such as PNS, PRP, Ultrasonics, and international business [11][12] - The focus will be on driving above-market growth across core businesses, particularly the HA franchise, while also investing in marketing and R&D to support growth [11][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and strong foundation, indicating a focus on becoming a $1 billion leading med tech company [5][18] - The company anticipates earnings growth to outpace revenue growth, maintaining an EBITDA margin of approximately 20% for 2026 [17][18] - Management highlighted the importance of leveraging profitable growth to fund future growth drivers, emphasizing a long-term approach to business [40] Other Important Information - The company refinanced its term loan, enhancing liquidity and driving interest expense savings [10] - The company expects net sales for 2026 to range from $600 million to $610 million, with adjusted earnings per share projected at $0.73 to $0.77 [27][28] Q&A Session Summary Question: Growth contribution year-over-year from price in pain treatments - Management indicated that growth was primarily driven by volume, with DUROLANE leading performance [34][35] Question: Assumptions by segment for 2026 growth - Management expects low to mid-single digit growth in restorative therapies and mid to high single digit growth in the pain portfolio, with double-digit growth anticipated in surgical solutions [36][38] Question: Impact of favorable order timing in Q4 - Management estimated that favorable order timing contributed approximately $2 million to growth in Q4 [45] Question: Learnings from the PNS pilot phase - Positive feedback was received regarding the technology's power, size, and ease of use, with plans to scale the business aggressively based on these insights [48][50]

Financial Data and Key Metrics Changes - Bioventus reported Q4 2024 revenue of $154 million, a 14% increase year-over-year, with adjusted EBITDA of over $28 million, reflecting a 28% increase compared to the prior year [31][36] - The company achieved adjusted gross margin of 74%, expanding 230 basis points compared to last year [35] - Adjusted net income more than doubled to $13 million, with adjusted earnings per share at $0.15 for the quarter, almost doubling compared to the prior year [36] Business Line Data and Key Metrics Changes - Surgical Solutions revenue accelerated by 18%, with Ultrasonics revenue advancing by more than 20% for the second consecutive quarter [31][32] - Pain Treatments revenue increased by 17%, driven by DUROLANE's strong brand recognition and clinical differentiation [32] - Restorative Therapies sales were flat compared to the prior year, with growth in Exogen offset by a decline in advanced rehabilitation due to divestiture [34] Market Data and Key Metrics Changes - The International segment grew 11% compared to the prior year, benefiting from delayed shipments in the Ultrasonics business [35] - The overall market for Bioventus's products is growing at low to mid-single digits, while the company expects to achieve above-market growth [21] Company Strategy and Development Direction - Bioventus aims to drive above-market revenue growth through diverse growth drivers and enhance profitability while accelerating cash flow [9][20] - The company completed a comprehensive review of its markets and established a framework for sustained and profitable growth, focusing on organic and inorganic opportunities [11] - Key areas of focus include strategic marketing, commercial effectiveness, and medical education to raise awareness about the benefits of ultrasonic surgery [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to build on positive momentum in 2025, with expectations for continued revenue growth and improved profitability [9][20] - The company plans to maintain high gross margins while focusing on supply chain improvements and aims for 100 basis points of incremental adjusted EBITDA margin improvement in 2025 [27] - Management highlighted the importance of maintaining focus on core business areas and executing growth strategies effectively [39] Other Important Information - The company paid down nearly $50 million in debt in Q4 2024, reducing its net leverage ratio to slightly above 3 turns [19] - For 2025, Bioventus expects net sales in the range of $560 million to $570 million, with adjusted EBITDA between $112 million and $116 million [40][41] Q&A Session Summary Question: Guidance assumptions by segment in 2025 - Management confirmed expectations of mid- to high single digits in pain treatments, low double digits in surgical, and low single digits in restorative therapies [48] Question: Impact of market shifts on HA and DUROLANE performance - Management indicated confidence in HA business growth driven by volume, with stable pricing expected [52] Question: Capital allocation priorities and debt reduction - Management emphasized the importance of reducing debt for financial flexibility while remaining focused on executing business goals [56][58] Question: Trends in bone graft substitutes and growth confidence - Management expressed optimism about the bone graft substitutes business, expecting it to return to double-digit growth in the second half of 2025 [62] Question: Growth expectations for Exogen - Management highlighted the turnaround in Exogen, expecting growth in the low to mid-single digits for 2025 [68] Question: International expansion plans - Management plans targeted geographic expansion internationally, emphasizing the need for high ROI investments [80] Question: Timeline for expanding Ultrasonic technology into general and neurosurgery - Management indicated that while the focus remains on spine surgery, there are plans to penetrate general and neurosurgery segments in the coming years [84]

Financial Data and Key Metrics Changes - The company reported revenue of $154 million for the fourth quarter, representing a 14% increase year-over-year [31] - Adjusted EBITDA for the fourth quarter was over $28 million, reflecting a 28% increase compared to the prior year [31] - Adjusted gross margin expanded by 230 basis points to 74% [35] - Adjusted net income more than doubled to $13 million, with adjusted earnings per share at $0.15 for the quarter [36] Business Line Data and Key Metrics Changes - Surgical Solutions revenue accelerated by 18%, with Ultrasonics achieving over 20% growth for the second consecutive quarter [31][32] - Pain Treatments revenue increased by 17%, driven by DUROLANE's strong brand recognition and clinical differentiation [32] - Restorative Therapies sales were flat year-over-year, with growth in Exogen offset by a decline in advanced rehabilitation [34] - Bone Graft Substitutes are expected to return to double-digit growth in the second half of 2025 [32] Market Data and Key Metrics Changes - The International segment grew by 11% compared to the prior year, benefiting from delayed shipments in the Ultrasonics business [35] - The overall market for the company's products is growing at low to mid-single digits, while the company expects to achieve above-market growth [21] Company Strategy and Development Direction - The company aims to drive above-market revenue growth, expand profitability, and accelerate free cash flow generation in 2025 [20] - A comprehensive review of all markets has established a framework for sustained and profitable growth, aligning the organization around a common vision [11] - The company is focusing on strategic marketing, commercial effectiveness, and medical education to raise awareness about its technology [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to build on positive momentum and deliver above-market growth [9] - The company is optimistic about the Bone Graft Substitutes business, expecting increased productivity from existing distributors and onboarding new customers [62] - Management highlighted the importance of maintaining focus on core business areas while exploring international expansion opportunities [80] Other Important Information - The company paid down nearly $50 million in debt during the fourth quarter, reducing its net leverage ratio to slightly above 3 turns [19] - For 2025, the company expects net sales in the range of $560 million to $570 million, reflecting organic growth of approximately 6% to 8% [40] Q&A Session Summary Question: Can you walk through the guidance assumptions by segment in '25? - Management confirmed expectations of mid- to high single digits in pain treatments, low double digits in surgical, and low single digits in restorative therapies [48] Question: How should we think about HA and DUROLANE performance in 2025? - Management expects HA growth to be driven by volume, with stable pricing, and anticipates above-market growth for DUROLANE [51][52] Question: When should investors expect capital allocation priorities to shift? - Management indicated that as debt is reduced, there will be increased financial flexibility to pursue strategic opportunities [56] Question: How are you thinking about the Bone Graft Substitute business trending this year? - Management expressed confidence in overcoming previous supply challenges and expects double-digit growth in the back half of 2025 [62] Question: Can you discuss trends in the Exogen business? - Management noted that Exogen has stabilized and is expected to grow in the low to mid-single digits, with a focus on maintaining growth momentum [68] Question: How will you drive OUS expansion in 2025 and beyond? - Management plans to be targeted in geographic expansion and is optimistic about international growth opportunities [80]